MX2023012032A - Composiciones y métodos para tratar la miastenia gravis pediátrica. - Google Patents

Composiciones y métodos para tratar la miastenia gravis pediátrica.

Info

Publication number
MX2023012032A
MX2023012032A MX2023012032A MX2023012032A MX2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A MX 2023012032 A MX2023012032 A MX 2023012032A
Authority
MX
Mexico
Prior art keywords
compositions
methods
myasthenia gravis
treating pediatric
pediatric
Prior art date
Application number
MX2023012032A
Other languages
English (en)
Spanish (es)
Inventor
Yaowei Zhu
Sindhu Ramchandren
Shawn Black
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2023012032A publication Critical patent/MX2023012032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023012032A 2021-04-12 2022-04-12 Composiciones y métodos para tratar la miastenia gravis pediátrica. MX2023012032A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US202263266880P 2022-01-18 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (1)

Publication Number Publication Date
MX2023012032A true MX2023012032A (es) 2023-12-08

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012032A MX2023012032A (es) 2021-04-12 2022-04-12 Composiciones y métodos para tratar la miastenia gravis pediátrica.

Country Status (13)

Country Link
US (1) US20240182598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517087A (cg-RX-API-DMAC7.html)
KR (1) KR20230169207A (cg-RX-API-DMAC7.html)
AU (1) AU2022256389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003033A1 (cg-RX-API-DMAC7.html)
IL (1) IL307445A (cg-RX-API-DMAC7.html)
JO (1) JOP20230247A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012032A (cg-RX-API-DMAC7.html)
PH (1) PH12023552841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法

Also Published As

Publication number Publication date
AU2022256389A9 (en) 2023-12-07
KR20230169207A (ko) 2023-12-15
JOP20230247A1 (ar) 2023-10-12
JP2024517087A (ja) 2024-04-19
EP4323002A4 (en) 2025-04-16
PH12023552841A1 (en) 2024-05-20
WO2022221239A1 (en) 2022-10-20
BR112023021046A2 (pt) 2023-12-19
US20240182598A1 (en) 2024-06-06
AU2022256389A1 (en) 2023-11-30
CL2023003033A1 (es) 2024-03-08
IL307445A (en) 2023-12-01
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
DOP2024000220A (es) Anticuerpos il-11
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
AR122784A2 (es) Inhibidores de kras g12c y métodos para su uso
IL285923A (en) Compositions, methods, and kits for delivery of polyribonucleotides
CY1121197T1 (el) Il2rbhta/koinhς γαμμα αλυσου αντισωματα
DOP2020000236A (es) Anticuerpos il-1 1ra
MX2019004690A (es) Constructos de anticuerpos.
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
SA518400103B1 (ar) مستضد غشاء محدد للبروستات يستهدف عوامل الترابط الشديد للمعالجة الإشعاعية الداخلية لسرطان البروستات
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
CO2023015915A2 (es) Anticuerpos anti-ccr8
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
MX2020010946A (es) Anticuerpos multiespecificos y usos del mismo.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
MX2017016349A (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
IL281504A (en) Methods and kits for preparing pathogen-inactivated whole blood
IL304403A (en) Multispecific antibodies having specificity for ror1 and cd3
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CL2023003033A1 (es) Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica.
UY39324A (es) Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.